SEC Form 4 · accession 0002039891-26-000006
Nuvation Bio Inc. · NUVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philippe Sauvage
Officer — Chief Financial Officer
Period of report
Jun 23, 2026
Accepted (ET)
Jun 24, 2026 · 7:07 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001811063
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 23, 2026 | M | 47,668 | $2.17 | A | 60,341 | D | |
| Class A Common StockF2 | Jun 23, 2026 | S | 47,668 | $6.0076 | D | 12,673 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.17 | Jun 23, 2026 | M | 47,668 | D | — | Oct 6, 2034 | Class A Common Stock | 47,668 | 702,332 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
- F2Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.04. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.